PEMT and metabolic dysfunction-associated steatotic liver disease: Remarkably, fenofibrate strongly reduced expression of markers for hepatic fibrosis in Pemt−/− mice when treatment was started after NAFLD was established, indicating a regression of hepatic fibrosis.